BridgeBio Pharma, Inc. (NASDAQ:BBIO) Given Average Recommendation of “Moderate Buy” by Brokerages

Shares of BridgeBio Pharma, Inc. (NASDAQ:BBIO) have been given a consensus recommendation of “Moderate Buy” by the twenty-three analysts that are presently covering the firm, Marketbeat reports. One equities research analyst has rated the stock with a sell recommendation and twenty-two have assigned a buy recommendation to the company. The average twelve-month price target among brokers that have covered the stock in the last year is $82.50.

A number of analysts have recently issued reports on the stock. HC Wainwright raised their target price on shares of BridgeBio Pharma from $90.00 to $100.00 and gave the stock a “buy” rating in a research note on Tuesday, February 17th. Oppenheimer decreased their price target on shares of BridgeBio Pharma from $83.00 to $81.00 and set an “outperform” rating on the stock in a research note on Wednesday, February 25th. Weiss Ratings reissued a “sell (d-)” rating on shares of BridgeBio Pharma in a report on Wednesday, January 21st. TD Cowen restated a “buy” rating on shares of BridgeBio Pharma in a report on Monday, January 12th. Finally, JPMorgan Chase & Co. upped their target price on BridgeBio Pharma from $76.00 to $77.00 and gave the company an “overweight” rating in a research report on Friday, November 7th.

BridgeBio Pharma Trading Down 1.2%

BBIO opened at $65.36 on Friday. The stock’s fifty day simple moving average is $73.64 and its 200 day simple moving average is $65.22. BridgeBio Pharma has a 1-year low of $28.33 and a 1-year high of $84.94. The stock has a market cap of $12.67 billion, a PE ratio of -17.29 and a beta of 1.13.

BridgeBio Pharma (NASDAQ:BBIO) last released its quarterly earnings data on Tuesday, February 24th. The company reported ($1.00) EPS for the quarter, missing analysts’ consensus estimates of ($0.75) by ($0.25). The business had revenue of $154.18 million for the quarter, compared to analysts’ expectations of $150.71 million. During the same period last year, the business posted ($1.40) earnings per share. BridgeBio Pharma’s revenue for the quarter was up 2521.2% on a year-over-year basis. Equities analysts forecast that BridgeBio Pharma will post -3.67 earnings per share for the current year.

Insider Buying and Selling at BridgeBio Pharma

In other news, CAO Maricel Apuli sold 510 shares of BridgeBio Pharma stock in a transaction on Tuesday, February 17th. The stock was sold at an average price of $74.31, for a total transaction of $37,898.10. Following the completion of the sale, the chief accounting officer owned 123,945 shares of the company’s stock, valued at approximately $9,210,352.95. This trade represents a 0.41% decrease in their ownership of the stock. The transaction was disclosed in a filing with the Securities & Exchange Commission, which can be accessed through this hyperlink. Also, CFO Thomas Trimarchi sold 13,600 shares of the company’s stock in a transaction dated Tuesday, February 17th. The shares were sold at an average price of $74.72, for a total transaction of $1,016,192.00. Following the completion of the transaction, the chief financial officer owned 336,585 shares in the company, valued at $25,149,631.20. This trade represents a 3.88% decrease in their ownership of the stock. Additional details regarding this sale are available in the official SEC disclosure. Insiders sold a total of 229,095 shares of company stock worth $16,247,760 in the last 90 days. Company insiders own 18.20% of the company’s stock.

Institutional Trading of BridgeBio Pharma

A number of institutional investors have recently bought and sold shares of BBIO. Global Retirement Partners LLC increased its holdings in shares of BridgeBio Pharma by 271.5% during the fourth quarter. Global Retirement Partners LLC now owns 509 shares of the company’s stock worth $39,000 after purchasing an additional 372 shares during the period. Farther Finance Advisors LLC boosted its stake in shares of BridgeBio Pharma by 91.4% in the fourth quarter. Farther Finance Advisors LLC now owns 513 shares of the company’s stock valued at $39,000 after buying an additional 245 shares during the period. Kemnay Advisory Services Inc. acquired a new stake in BridgeBio Pharma during the fourth quarter worth approximately $41,000. Cary Street Partners Investment Advisory LLC grew its position in BridgeBio Pharma by 861.0% during the fourth quarter. Cary Street Partners Investment Advisory LLC now owns 567 shares of the company’s stock worth $43,000 after buying an additional 508 shares in the last quarter. Finally, Eurizon Capital SGR S.p.A. bought a new position in BridgeBio Pharma during the 4th quarter worth $44,000. Institutional investors own 99.85% of the company’s stock.

About BridgeBio Pharma

BridgeBio Pharma, Inc is a clinical-stage biopharmaceutical company headquartered in Palo Alto, California. Founded in 2015 by Neil Kumar, the company is dedicated to discovering, developing and delivering transformative medicines for patients with genetic diseases and cancers. BridgeBio operates an integrated model that spans target identification, preclinical research, clinical development and commercialization, aiming to streamline the process from bench to bedside.

BridgeBio’s pipeline comprises multiple therapeutic modalities, including small molecules, biologics and genetic therapies.